This bill updates two pieces of statute tied to the federal stem‑cell infrastructure. It changes the appropriation language for section 379B of the Public Health Service Act (the C.W.
Bill Young Cell Transplantation Program) to preserve the existing $31,009,000 level and to add a separate line of $33,009,000 for each fiscal year 2027 through 2031. Separately, it amends the Stem Cell Therapeutic and Research Act of 2005 to extend the statutory reference to the federal cord blood inventory from 2026 to 2031.
Why it matters: the measure supplies a modest, multi‑year funding boost to the public marrow and cord‑blood ecosystem and locks in statutory authority for the national cord‑blood inventory for five additional years. The changes are narrow and programmatic — they adjust money and dates rather than altering program structure, reporting, or eligibility rules — so the practical effect will be felt primarily by program managers, public cord‑blood banks, transplant centers, and the patients who depend on an available and diverse inventory of units.
At a Glance
What It Does
Amends 42 U.S.C. 274m (section 379B of the Public Health Service Act) to add a second appropriation paragraph: $33,009,000 for each of FY2027–FY2031 while retaining the current $31,009,000 figure. It also amends section 2(g) of the Stem Cell Therapeutic and Research Act of 2005 to change the statutory year reference from 2026 to 2031, effectively extending the cord‑blood inventory authorization.
Who It Affects
HRSA and the C.W. Bill Young Cell Transplantation Program administrators, public cord‑blood banks and inventory managers, transplant registries and centers that rely on publicly listed cord blood and marrow units, and patients seeking hematopoietic stem‑cell transplants — especially those needing diverse HLA matches.
Why It Matters
The bill converts a single‑year funding statement into a multi‑year authorization with a small per‑year increase (about $2 million) for five years and extends statutory authorization for the public cord‑blood inventory. For compliance officers and program leaders, this creates predictable but limited additional resources and an extended planning horizon through 2031 without changing program rules or oversight requirements.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill performs two surgical fixes to the federal framework that supports public stem‑cell resources. First, it revises the appropriation language in section 379B of the Public Health Service Act so that the statute now lists two appropriation lines: the existing $31,009,000 figure and a new recurring amount of $33,009,000 for each fiscal year 2027 through 2031.
Practically, that means Congress would have explicit statutory language authorizing slightly higher funding for the C.W. Bill Young Cell Transplantation Program for five years, though actual funds still flow through the annual appropriations process.
Second, the bill amends a date in the Stem Cell Therapeutic and Research Act of 2005 by replacing the terminal year “2026” with “2031” in the provision that governs the cord‑blood inventory. That amendment extends the statutory timeframe for activities tied to maintaining and expanding the national cord‑blood inventory without adding new programmatic mandates, reporting duties, or eligibility changes.Together the changes give the federal program a modest budget uplift and a longer authorization horizon.
The text does not direct how the extra dollars must be spent, nor does it create new oversight structures; those operational choices remain with the administering agency and with Congress through appropriations language. The net effect is incremental: more stable near‑term funding and an extended statutory mandate for the cord‑blood inventory, intended to support patient access to publicly banked units and the system that recruits, stores, and lists them.
The Five Things You Need to Know
The bill amends 42 U.S.C. 274m (section 379B of the Public Health Service Act) by replacing a single appropriation statement with two numbered paragraphs.
It adds an explicit appropriation of $33,009,000 for each fiscal year 2027 through 2031 — $2,000,000 more per year than the cited $31,009,000 figure.
The existing $31,009,000 figure remains in the statutory text (retained as the first numbered paragraph).
Section 3 changes the year “2026” to “2031” in section 2(g) of the Stem Cell Therapeutic and Research Act of 2005, extending the cord‑blood inventory’s statutory reference period by five years.
The bill confines its changes to funding levels and a statutory date; it does not alter program authorities, eligibility, reporting requirements, or the administrative structure of the transplantation program.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the Act’s citation: "Stem Cell Therapeutic and Research Reauthorization Act of 2026." This is a formal label only and has no substantive effect on program operations or funding mechanics.
Adds multi‑year appropriation line for the C.W. Bill Young Cell Transplantation Program
This amendment rescinds the single‑line appropriation language and replaces it with two numbered paragraphs: the first preserves the previously cited $31,009,000 and the second establishes $33,009,000 for each fiscal year 2027–2031. Mechanically, the statute will now list both amounts, signaling congressional intent for slightly higher FY27–FY31 funding. The practical implication is budget predictability at a modestly elevated level, but the amounts still require passage of appropriation acts to be funded.
Extends the cord‑blood inventory statutory period to 2031
Section 3 amends section 2(g) of the 2005 Act by changing the terminal year from 2026 to 2031. That textual change extends the statutory reference to the cord‑blood inventory for five additional years. The amendment does not specify new program priorities or uses for the cord‑blood inventory funds; it merely lengthens the period during which related activities are referenced in statute, which reduces the immediate need for another reauthorization in the short term.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients needing hematopoietic stem‑cell transplants — a modestly improved chance of access to publicly banked cord‑blood and marrow units due to continued support for national inventory management and registry functions.
- Public cord‑blood banks and inventory managers — greater near‑term budget clarity and an incremental funding increase to support collection, storage, and listing operations for five more years.
- Transplant registries and program administrators (C.W. Bill Young program/HRSA) — a predictable authorization path that eases short‑term planning for outreach, recruitment, and inventory maintenance.
- Transplant centers and hospitals — continued federal support maintains availability of listed units they rely on for patient matching and reduces the risk of sudden funding gaps that could disrupt supply.
- Researchers and public‑health planners focused on donor diversity — continued authorization preserves public inventory programs that can be targeted toward underrepresented HLA types.
Who Bears the Cost
- Federal discretionary budget — the appropriation lines increase authorized spending by roughly $2 million annually for FY2027–FY2031, which must be absorbed within overall appropriations decisions.
- Appropriations committees and budget drafters — will need to account for the authorization in fiscal planning and prioritize within competing demands.
- Program administrators (HRSA and contractors) — managing and allocating additional funds and maintaining expanded inventory may incur administrative and compliance costs if new activities are funded without accompanying operational guidance.
- Private cord‑blood banks and commercial registries — may face competitive pressure as public inventory programs receive additional federal support without parallel incentives for private providers, potentially affecting market dynamics.
Key Issues
The Core Tension
The central tension is between providing short‑term stability for publicly accessible stem‑cell resources and the need for substantive program reform: modest, multi‑year funding preserves inventory and access in the near term, but without stronger programmatic direction or evaluation metrics the increase may not address gaps in diversity, efficiency, or long‑term sustainability.
Two practical tensions stand out. First, the bill authorizes money but does not appropriate it.
Listing $33,009,000 for FY2027–FY2031 signals congressional intent but does not guarantee funding; actual cash flow depends on future appropriation acts and any direction included in those bills. That gap between authorization and appropriation matters for program planning: administrators can plan on a clearer horizon, but they lack ironclad funding until appropriations are enacted.
Second, the measure extends the cord‑blood inventory timeline without addressing program performance, priority setting, or accountability. The statute will authorize more time and a modest funding increase, but it leaves unresolved how dollars should be targeted (for example, toward increasing racial and ethnic diversity in stored units, improving HLA‑typing, scaling transportation logistics, or bolstering inventory quality).
The narrowness of the changes risks perpetuating inefficiencies if program managers do not receive clearer policy direction or data‑driven spending criteria.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.